Pratia Hematologia Sp. z o.o. — Clinical Trial Site

89 Registered trials

46 Currently recruiting

Organisation

Pratia Hematologia Sp. z o.o.

Location

Katowice, Poland

Identifier

ORG-100040044

Address

Ul. Tadeusza Kosciuszki 92, 40-519, Poland

Departments

-
#5704 Pratia Onkologia Katowice
#9008: oncology
2141: PRATIA Onkologia Katowice
2806 : Pratia Onkologia Katowice
5702: Hematologia
Hematologia
Hematology
n/a
NA
PL30001:Oncology
Poradnia Onkologiczna
Pratia Onkologia Katowice
Pratia Hematologia Sp. z o.o.
Pratia Onkologia
Pratia Onkologia Katowice
Site name:Pratia Onkologia Katowice, ul. Kosciuszki 92, 40-519 Katowice

Clinical trials at this site (89)

Search interface

A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat… Ended

2023-507698-16-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-10-14
A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended

2023-507697-40-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2021-07-05
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto… Ended

2023-503916-33-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2021-03-24
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16
Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended

2023-507153-16-00 Higher-Risk Myelodysplastic Syndrome 5 2020-11-18
Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended

2023-504828-25-00 Chronic Lymphocytic Leukemia 9 2020-11-16
PACIFICA: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thro… Ended

2024-515953-52-00 Post-Essential Thrombocythaemia Myelofibrosis 5 2020-07-24
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu… Ended

2023-505321-14-00 Warm Autoimmune Hemolytic Anemia 10 2019-09-06
A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended

2023-508759-38-00 Relapsed/Refractory B-cell Malignancies 1 2025-06-04
A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo… Ended

2023-505910-10-00 Relapsed or Refractory High-Risk Myelodysplastic Syndro 4 2024-01-23
Asciminib treatment optimization in ≥ 3rd line CML-CP Ended

2024-511381-36-00 Chronic Myelogenous Leukemia in chronic phase (CML-CP) 5 2021-10-13
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended

2023-507086-26-00 Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse 7 2021-03-09
A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Parti… Ended

2024-512687-66-00 non-Hodgkin lymphoma and chronic lymphocytic leukemia 3 2021-02-16
A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma … Ended

2024-512686-13-00 non-Hodgkin lymphoma and chronic lymphocytic leukemia 3 2021-01-28
A long-term study to assess the safety and efficacy of efgartigimod in adult patients with primary immune thrombocytopenia (an autoimmune di… Ended

2024-511504-17-00 Primary immune thrombocytopenia 5 2020-12-15
Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective pha… Ended

2023-509737-39-00 Primary infection prophylaxis in patients with chronic 5 2020-08-19